About | Free Trial

Last Update

2016-04-28T00:00:00.000Z

This profile was last updated on . .

Is this you? Claim your profile.

Wrong David Hallal?

Mr. David Hallal L.

Chief Executive Officer

Alexion Pharmaceuticals Inc

Direct Phone: (203) ***-****       

Email: d***@***.com

Alexion Pharmaceuticals Inc

352 Knotter Drive

Cheshire, Connecticut 06511

United States

Company Description

Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company engaged in the discovery, development and delivery of biologic therapeutic products for the treatment disease, including hematologic and neurologic diseases, cancer and autoimmune diso... more

Find other employees at this company (2,994)

Background Information

Employment History

Director of Sales
Eyetechs Inc

Leadership Positions
Eli Lilly and Company

Education

BA

University of New Hampshire

Web References (199 Total References)


Alexion Pharmaceuticals CEO ...

regulatoryaffairs.pharmaceutical-business-review.com [cached]

Alexion Pharmaceuticals CEO David Hallal said: "We are pleased with the FDA approval of Kanuma, a transformative treatment for patients with LAL-D, a devastating, ultra-rare disease that causes premature death in infants and multi-organ damage in those who survive.


Alexion Pharmaceuticals CEO ...

regulatoryaffairs.pharmaceutical-business-review.com [cached]

Alexion Pharmaceuticals CEO David Hallal said: "As the first approved treatment for pediatric-onset HPP in Europe, Strensiq is an innovative therapy for patients suffering from this devastating and life-threatening ultra-rare disease.

...
Hallal said: "In the absence of any effective therapy, patients with LAL-D face devastating morbidities including liver failure and premature mortality.


Alexion Reports First Quarter 2016 Results | Business Wire

feeds.businesswire.com [cached]

We are very pleased with the strong start to the Strensiq launches in initial countries and have now commenced the U.S. launch of Kanuma," said David Hallal, Chief Executive Officer of Alexion.


Alexion Reports First Quarter 2016 Results | Business Wire

feeds.businesswire.com [cached]

We are very pleased with the strong start to the Strensiq launches in initial countries and have now commenced the U.S. launch of Kanuma," said David Hallal, Chief Executive Officer of Alexion.


...

www.sec.gov [cached]

0001457477 Hallal David C/O ALEXION PHARMACEUTICALS, INC 100 COLLEGE STREET NEW HAVEN CT 06510 1 1 0 0 CEO

Similar Profiles

Other People with this Name

Other people with the name Hallal

Alexcia Hallal
Premier Strata Management Pty Ltd

Firas Hallal
Aiwa Gulf

Jayme Gnoatto Hallal
Olam Brasil Ltda

John Hallal
Network Blue Inc

Sagar Hallal
New Leaf Ayurveda

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory